tiapridex and Breast-Neoplasms

We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease. The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy. She also had advanced breast cancer when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other neuroleptic drugs, particularly in patients with a worsening general condition.

Topics: Adrenergic Uptake Inhibitors; Adult; Aged, 80 and over; Antipsychotic Agents; Breast Neoplasms; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Huntington Disease; Middle Aged; Neoplasm Recurrence, Local; Neuroleptic Malignant Syndrome; Tetrabenazine; Tiapride Hydrochloride